On Feb. 25th, we are excited to have Dr. Eva Jingyi Liu, Senior Manager, Merck Innovation Hub China and Dr. Xianglong Zhao from Bio-X Institutes of Shanghai Jiao Tong University as our panel discussion speakers to discuss the application of organoids in tumor drug development and precision clinical medicine. Merck will also introduce their Accelerator program and answer questions regarding the program recruiting criteria and other details.

我们有幸邀请到默克中国创新中心高级经理刘静逸博士和上海交通大学Bio-X研究院的赵祥龙博士，在2月25日周四晚，共同探讨类器官芯片在肿瘤药物研发和临床精准医疗中的应用。当天，默克也将带来新一轮默克中国加速器项目的介绍，解答加速器项目招募和申请标准及项目细节。On Feb. 25th, we are excited to have Dr. Eva Jingyi Liu, Senior Manager, Merck Innovation Hub China and Dr. Xianglong Zhao from Bio-X Institutes of Shanghai Jiao Tong University as our panel discussion speakers to discuss the application of organoids in tumor drug development and precision clinical medicine. Merck will also introduce their Accelerator program and answer questions regarding the program recruiting criteria and other details.

我们有幸邀请到默克中国创新中心高级经理刘静逸博士和上海交通大学Bio-X研究院的赵祥龙博士，在2月25日周四晚，共同探讨类器官芯片在肿瘤药物研发和临床精准医疗中的应用。当天，默克也将带来新一轮默克中国加速器项目的介绍，解答加速器项目招募和申请标准及项目细节。

Language 活动语言

Chinese中文

Time and Location 时间地点

2/25, Thursday, 7-9 pm

OnePiece Work

7F, 222 Hubin Rd, Link Square 1, Huangpu District - Entrance from Hubin Rd

黄浦区，领展企业天地1号楼7层 - 从湖滨路进入

Register for offline event:

https://app.glueup.cn/event/30378/register/

Register for the online webinar if you cannot attend in person （8-9 PM) :

如果您无法到现场，可通过以下链接或上方二维码注册在线观看（晚上8-9点):

https://zoom.us/meeting/register/tJArfuCsqDkiG9WLreRIvPndf1VgOOyISXxs

Event Agenda

活动安排

7:00PM Networking, wine and light dinner

观众注册，酒水及晚餐

8:00PM Fireside Chat and Q&A

炉边访谈及问答

9:00PM Discussion and networking

自由互动环节

About the Speakers 关于演讲者

Dr. Eva Jingyi Liu, Senior Manager, Merck Innovation Hub China

Eva is MD/PhD in Neurology of Clinical Medicine from The Chinese University of Hong Kong, and a Bachelor of Medicine / Bachelor of Surgery degree (MBBS) from Peking University.

She was responsible for strategic investment in BGI, worked on investment deals in pharmaceutical and life science relevant fields like in vitro diagnostics, genetic therapy, cancer immunotherapy, innovation devices and assisted reproductive technology. She was responsible for management consulting & due diligence in IMS/IQVIA, conducted strategic planning for healthcare and life sciences corporates.

She had working experience as a neurologist in Hong Kong Prince of Wales Hospital, Beijing Jishuitan Hospital and New Zealand Auckland City Hospital during MD/PhD study.

In Merck, she is responsible for investment expertise in innovation fields relevant to Merck sectors, and has broad understanding in organoids, IVD and gene and cellular therapy related areas as well.

刘静逸，医学博士，默克中国创新中心高级经理

刘静逸博士拥有香港中文大学医学院临床医学博士学位，北京大学医学院临床医学学士学位。

她曾在华大基因(BGI) 负责战略投资及并购上市，主导生物制药及生命科学相关领域的投资/上市交易，包括体外诊断，基因治疗，肿瘤细胞免疫治疗，创新器械/设备，辅助生殖等。在IMS/IQVIA负责管理咨询及商业尽调，负责医疗健康及生命科学领域跨国外企战略规划，新品上市，政策分析等及医疗投资领域商业尽调。

拥有北京积水潭医院，香港威尔斯亲王医院，新西兰奥克兰城市医院神经内科专科临床医生工作经验。

在默克，刘静逸博士不仅建立了与默克业务相关创新领域的投资专业知识，而且在类器官，体外诊断，基因&细胞治疗相关的领域也拥有专业经验。

Dr. Xianglong Zhao is currently in charge of the establishment of stem cell and organoid platform and organoid chip research at the Personalized Medicine Center (PMC) of Bio-X Institutes of Shanghai Jiaotong University. Before this, he worked at the Gynecology Research Institute of the Third Affiliated Hospital of Guangzhou Medical University's experimental platform, responsible for the management of scientific research teams and interpretation of genetic testing data.

Dr. Zhao is currently a postdoctoral fellow at the Personalized Medicine Center jointly established by Harvard University Broad and Shanghai Jiao Tong University Bio-X Institutes. He has long been engaged in DNA genetics and gene chip related research and participated in publishing 12 Sci papers with a cumulative impact factor of 32. . Currently participating in the international gene database construction project, with a research funding of 4 million US dollars (27.75 million yuan), and has won the Shanghai "Entrepreneurship Qualification Certificate".

The research projects that Dr. Zhao is focused on mainly include: the screening and application of schizophrenia drugs based on organoid chips; application of pharmacogenomics in personalized medicine; market development and clinical application research of domestic genetic testing products.

赵祥龙博士目前在上海交通大学Bio-X研究院个体化医学中心（PMC）负责干细胞和类器官平台建立和类器官芯片研究工作。曾在广州医科大学附属第三医院妇科研究所实验平台，负责科研团队管理，基因检测数据解读工作。

赵博士目前在哈佛大学Broad和上海交通大学Bio-X研究院共建的个体化医学中心读博士后，长期从事DNA遗传学和基因芯片相关领域研究，参与发表Sci论文12篇，累计影响因子32分。目前参与国际基因数据库构建工程，科研经费400万美元（2775万元人民币），个人荣获上海市《创业资格证书》。

赵博士负责的研究项目主要有：基于类器官芯片的精神分裂症药物的筛选和应用；药物基因组学在个体化医学中的应用；国内基因检测产品的市场开发和临床应用研究等。

About Merck Accelerator

关于默克加速器

The objective of the Accelerator program is to identify promising startups, connect them to relevant business sectors and build pilot projects to foster innovation projects of Merck and its three business sectors for co-development and a sustainable business partnership. The six-month Merck China Accelerator runs once a year with a focus on startups in the seed to series A financing round in the fields of healthcare, performance materials, life sciences, AI-enabled health solutions, organoid, bioelectronics, liquid biopsy, neuromorphic system, and clean meat. The application for the 4th intake of China Accelerator program is open for early application from Jan 25th, 2021, until Feb 25th, 2021. Apply now at 'Read more' at the bottom left of this article or scan the QR code below.

默克加速器项目作为链接默克与初创企业的纽带，致力于发掘有潜力的初创企业，为他们的业务发展提供支持并建立合作，共同探讨和推动为世界创造价值的创新商业机会。为期六个月的默克中国加速器每年进行一期，重点关注医药健康、生命科学、高性能材料、人工智能健康解决方案、类器官、生物电子、液体活检技术、神经形态系统和清洁肉等领域，处于种子期至A轮融资的初创公司。默克中国加速器第四期已开启预申请，招募时间为2021年1月25日-2月25日。点击“阅读原文”或扫码立即报名。

About Merck Innovation Hub China

关于默克创新中心

As an important part of Merck’s global innovation network, the China Innovation Hub scouts, incubates and invests in innovative opportunities in healthcare, life science, performance materials and related fields between and beyond the existing businesses. Embedded into China’s innovation ecosystem, Merck Innovation Hub China is committed to partnering with start-ups, academic institutions, industry players and local governments, combining unique technology and expertise from Merck Group and collaborators with the goal to develop novel technology and bring new solutions to the market for China and global. The China Innovation Hub also provides support of ideation, incubation and trainings to local talents, partners and Merck employees to build win-win collaboration. For more information, please visit http://innovateinchina.merckgroup.com.

默克中国创新中心是默克全球创新网络的一个重要部分，致力于搜寻、孵化和投资医药健康、生命科学、高性能材料以及现有业务领域之间和之外的创新机会。默克中国创新中心植根中国创新生态，积极与初创企业、学术机构、业内伙伴和当地政府建立合作伙伴关系，整合默克集团与合作伙伴在各自相关领域的独特技术和专业技能，开发创新技术，为中国市场和全球业务带来新的解决方案，同时为本地创新人才、合作伙伴和默克员工提供创意激发培养和创新孵化支持，实现合作共赢。关于默克中国创新中心的更多信息，请访问http://innovateinchina.merckgroup.com。

About Bio-X Institutes of Shanghai Jiao Tong University

关于上海交通大学Bio-X研究院

The Bio-X Institutes of Shanghai Jiao Tong University was formed in 2005 by merging the Neuropsychiatric and Human Genetics Group (NHGG), which was established in 1996, and the Bio-X Life Science Research Institutes, which was established in April 2000.

The founding of the Bio-X Institutes represents a landmark in interdisciplinary research among the life sciences. The mission of the Institutes is to provide not only an interdisciplinary institute but also to serve as a forum for discussion among scientists and students from a variety of disciplines and fields.

The current director of the Institutes is Prof. Lin He, a fellow of the Chinese Academy of Sciences, and the honorary director is Prof. Steve Zhu, physics Nobel Laureate.

The research at the Bio-X Institutes focuses on interdisciplinary topics between nutrition, health& disease, development and reproduction, biosaftey and DNA computing. More in detail, we currently have research programs in genome mapping and cloning, functional genomics, pharmacogenomics, proteomics, psychiatric metabolism, DNA computing, bioinformatics and nation-wide protection of genetic resources.

上海交通大学Bio-X研究院(以下简称“研究院”)是于2005年由NHGG(Neuropsychiatric and Human Genetics Group, 神经精神与人类遗传学研究室)和2000年成立的Bio-X生命科学研究中心经过重组凝练而成。自从谢绳武校长亲自宣布了“研究院”的成立起，标志了我校正式启动了生命学科与其他多学科间进行交叉合作研究基地的建设，开始起到成为从事与生命科学相关的多学科交叉研究科学家的工作平台的作用，并为不同学科和领域的研究人员和学生提供一个学术思想和信息交流的温馨的“家”。

研究院现届院长为贺林教授(中国科学院院士)，名誉院长为诺贝尔奖获得者朱棣文教授。

经过多年的摸索和实践，最终研究院把自己的研究方向定位在《疾病与健康》、《营养与健康》、《发育与生殖》、《生物安全(筹)》、《DNA计算与技术》的范畴，具体可分解为“基因定位与克隆”、“功能基因组学”、“药物基因组学”、“精神疾病代谢组学”、“蛋白质组学”、“动物模型”、“DNA计算与技术”、“生物信息学”、“全国遗传资源保护网”等课题。